-
公开(公告)号：US20240350672A1
公开(公告)日：2024-10-24
申请号：US18617239
申请日：2024-03-26
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Tongyao LIU , Ekta Seth CHHABRA , Siyuan TAN
IPC: A61K48/00 , A61K38/00 , A61P7/04 , C07K14/755 , C12N15/85
CPC classification number: A61K48/0058 , A61P7/04 , C07K14/755 , C12N15/85 , A61K38/00
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.
-
12.发明申请公开(公告)号：US20230002828A1
公开(公告)日：2023-01-05
申请号：US17681435
申请日：2022-02-25
Applicant: Bioverativ Therapeutics Inc. , Puget Sound Blood Center
Inventor： Haiyan JIANG , Tongyao LIU , Sriram KRISHNAMOORTHY , Neil JOSEPHSON , Glenn PIERCE
IPC: C12Q1/6883 , A61K38/21 , A61K39/00 , A61K38/37 , C07K14/755 , A61K47/68
Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
公开(公告)号：US20220106383A1
公开(公告)日：2022-04-07
申请号：US17479705
申请日：2021-09-20
Applicant: Bioverativ Therapeutics Inc.
Inventor： Ekta Seth CHHABRA , John KULMAN , Tongyao LIU
IPC: C07K14/755 , A61K38/37
Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
-
公开(公告)号：US20210115425A1
公开(公告)日：2021-04-22
申请号：US17060759
申请日：2020-10-01
Applicant: Bioverativ Therapeutics Inc.
Inventor： Siyuan TAN , Robert T. PETERS , Tongyao LIU
IPC: C12N9/64
Abstract: The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor IX nucleic acid sequence or the polypeptide encoded thereby.
-
公开(公告)号：US20200069817A1
公开(公告)日：2020-03-05
申请号：US16537192
申请日：2019-08-09
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Tongyao LIU , Alexey SEREGIN , Robert T. PETERS , Jiayun LIU , Philip ZAKAS , Douglas DRAGER , Susannah PATARROYO-WHITE
Abstract: The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and/or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.
-
Patent Agency Ranking
公开(公告)号：US20240124555A1
公开(公告)日：2024-04-18
申请号：US18364103
申请日：2023-08-02
Applicant: Bioverativ Therapeutics Inc.
Inventor： Siyuan TAN , Tongyao LIU
IPC: C07K14/755 , A61K48/00 , A61P7/04 , C12N7/00 , C12N15/86
CPC classification number: C07K14/755 , A61K48/0016 , A61K48/005 , A61P7/04 , C12N7/00 , C12N15/86 , A61K38/00 , C07K2319/30 , C07K2319/31 , C12N2740/16043 , C12N2800/22
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.
-
公开(公告)号：US20230019286A1
公开(公告)日：2023-01-19
申请号：US17240351
申请日：2021-04-26
Applicant: Bioverativ Therapeutics Inc.
Inventor： Volker SCHELLENBERGER , Pei-Yun CHANG , Fatbardha VARFAJ , John KULMAN , Tongyao LIU , Garabet G. TOBY , Haiyan JIANG , Robert PETERS , Deping WANG , Baisong MEI , Joshua SILVERMAN , Chia-Wei WANG , Benjamin SPINK , Nathan GEETHING
IPC: C07K14/755 , C07K14/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
公开(公告)号：US20220056108A1
公开(公告)日：2022-02-24
申请号：US17358142
申请日：2021-06-25
Applicant: Bioverativ Therapeutics Inc.
Inventor： Ekta Seth CHHABRA , Tongyao LIU , Pei-yun CHANG , Robert T. PETERS , John KULMAN , Haiyan JIANG
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号：US20210032616A1
公开(公告)日：2021-02-04
申请号：US16920970
申请日：2020-07-06
Applicant: Bioverativ Therapeutics Inc.
Inventor： Zhiqian LIU , Arjan VAN DER FLIER , David R. LIGHT , Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN , Ayman ISMAIL
Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
-
公开(公告)号：US20190315835A1
公开(公告)日：2019-10-17
申请号：US16369820
申请日：2019-03-29
Applicant: Bioverativ Therapeutics Inc.
Inventor： Volker SCHELLENBERGER , Pei-Yun CHANG , Fatbardha VARFAJ , John KULMAN , Tongyao LIU , Garabet G. TOBY , Haiyan JIANG , Robert PETERS , Deping WANG , Baisong MEI , Joshua SILVERMAN , Chia-Wei WANG , Benjamin SPINK , Nathan GEETHING
IPC: C07K14/755 , C07K14/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.025 seconds)
